Core Viewpoint - InMode reported quarterly earnings of $0.47 per share, exceeding the Zacks Consensus Estimate of $0.43 per share, and showing an increase from $0.34 per share a year ago, indicating a positive earnings surprise of +9.30% [1][2] Financial Performance - The company achieved revenues of $95.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.11%, and up from $86.45 million year-over-year [2] - Over the last four quarters, InMode has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - InMode shares have declined approximately 14.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $88.4 million, and for the current fiscal year, it is $1.68 on revenues of $365 million [7] Industry Context - The Medical - Products industry, to which InMode belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of InMode's stock may be influenced by the overall outlook of the industry [8]

Core Insights - InMode reported quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share, and down from $0.45 per share a year ago, representing an earnings surprise of -6.06% [1] - The company posted revenues of $77.87 million for the quarter, surpassing the Zacks Consensus Estimate by 0.61%, but down from $80.28 million year-over-year [2] - InMode has surpassed consensus revenue estimates four times over the last four quarters, while it has exceeded EPS estimates only twice [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.50 on revenues of $100.1 million, and for the current fiscal year, it is $1.83 on revenues of $383.8 million [7] - The estimate revisions trend for InMode is currently unfavorable, leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which InMode belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact InMode's stock performance [5]